Broad swathe of measures to support UK life sciences draws widespread applause
This article was originally published in Scrip
Broad approval has been expressed by industry to the UK government's newly unveiled strategy to boost the UK life sciences sector, along with a review of innovation in the National Health Service. Prime Minister David Cameron gave a speech underlining the importance of the industry, which employs over 160,000 people in more than 4,000 firms, generating total annual turnover of some £50 billion. The country's four main life science trade bodies, united under the banner LifeSciencesUK, welcomed the new initiatives, saying they would "stimulate interest and investment in the UK life sciences sector".
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.